CoChat
Sign Up
Cited by 107Bone Metabolism and DiseasesInflammatory mediators and NSAID effectsBone fractures and treatments

Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats

Tanaka, Masahiro, Sakai, Akinori, Uchida, Soshi, Tanaka, Shinya, Nagashima, Masato, Katayama, Teruaki, Yamaguchi, Kojiro, Nakamura, Toshitaka·2004·Bone
DOI 10.1016/j.bone.2004.01.002
Open this paper in CoChat — free account

Abstract

Prostaglandin E(2) (PGE(2)) is essential for fracture healing. Systemic administration of EP4 ligands such as PGE(2) and other synthetic EP4 agonists appears to transduce anabolic signals by binding to receptor EP4. Therefore, the present study was designed to test whether administration of EP4 agonist accelerates the healing of drill-hole injury in the femoral diaphysis. After surgery, a total of 128 Wistar rats, at the age of 12 weeks, were assigned to basal control (n = 8), and three groups with respective doses of 0 (vehicle control), 10 (low-dose), and 30 (high-dose) microg/kg body weight of the agent were subcutaneously injected twice a day. Femoral specimens were obtained at 0, 5, 7, 14, 21, and 28 days. In EP4 agonist-treated groups, the total bone volume of the regenerating bone in the defect did not significantly differ, but the regenerated cortical bone volume measured by histomorphometry and cortical bone mineral content (Ct. BMC) by pQCT dose-dependently increased at 14 and 21 days compared to the control. In the high-dose group, the value of osteoclast surface significantly increased compared with that in the control at 14 days. Expression levels of osteocalcin and TRAP mRNAs in the injured tissue increased at 14 days. Expression levels of EP4, BMP-2, and RANKL mRNAs increased at 7 days in the high-dose group. The bone mineral values of the lumbar bone at 28 days, measured by DXA, did not differ in the three groups. These data indicated that systemic administration of EP4 agonist ONO-4819.CD accelerated cortical bone healing after drill-hole injury by upregulating the local turnover of the regenerating bone.

Integrity signals

Registry

Crossref · 10.1016/j.bone.2004.01.002

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is a lack of evidence from clinical studies in patients for selective prostaglandin agonists, cyasterone, statins, and anti-sclerostin antibodies as fracture-healing accelerators.

    “Other drugs that have been considered to accelerate fracture healing include selective prostaglandin agonists (111), cyasterone (112), statins, and anti-sclerostin antibodies (113), but there is a lack of evidence from clinical studies in patients.”

    From Methods to accelerate fracture healing – a narrative review from a clinical perspective (2024) · cites this paper as [111]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Tanaka, M., Sakai, A., Uchida, S., Tanaka, S., Nagashima, M., Katayama, T., Yamaguchi, K., & Nakamura, T.
Affiliations
  • University of Occupational and Environmental Health Japan (JP)
  • Ono Pharmaceutical (Japan) (JP)
Corresponding author
Sakai, Akinori
ORCID
Venue
Bone
Publisher
Elsevier BV
Published
2004-06
Volume
34
Issue
6
Pages
940-948
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
DOI
10.1016/j.bone.2004.01.002
OpenAlex
W1964005120
Cited by
107
References
29
Citations by year
2025: 1 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 3 · 2012: 3
FWCI
2.84
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education and Science (12470313, 14370475)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Epidemiology › Bone fractures and treatments
Keywords
EP4 receptor, fracture healing, femoral diaphysis, bone turnover, osteoclasts, osteocalcin, traps, BMP-2, RANKL, bone mineral content, systemic administration
MeSH terms
Animals, Bone Regeneration, Femur, Heptanoates, Male, Up-Regulation, Bone Remodeling, Rats, Wistar, Receptors, Prostaglandin E, Rats, Receptors, Prostaglandin E, EP4 Subtype

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review